MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598760 | Name: LF 1695

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LF 1695 is a synthetic immunomodulator.

Chemical Structure

LF 1695
LF 1695
CAS#86187-86-2

Theoretical Analysis

MedKoo Cat#: 598760

Name: LF 1695

CAS#: 86187-86-2

Chemical Formula: C19H21ClN2O

Exact Mass: 328.1342

Molecular Weight: 328.84

Elemental Analysis: C, 69.40; H, 6.44; Cl, 10.78; N, 8.52; O, 4.87

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
LF 1695; LF-1695; LF1695;
IUPAC/Chemical Name
(5-amino-2-(4-methylpiperidin-1-yl)phenyl)(4-chlorophenyl)methanone
InChi Key
RTHJIPJVGHYRMG-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H21ClN2O/c1-13-8-10-22(11-9-13)18-7-6-16(21)12-17(18)19(23)14-2-4-15(20)5-3-14/h2-7,12-13H,8-11,21H2,1H3
SMILES Code
O=C(C1=CC(N)=CC=C1N2CCC(C)CC2)C3=CC=C(Cl)C=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
LF 1695 is a synthetic immunomodulator.
In vitro activity:
This was further confirmed by the fact that LF 1695 inhibited the second wave of platelet aggregation induced by ADP as well as arachidonic acid effects. Incubation of platelets with [14C]arachidonic acid in the presence of 60 microM LF 1695 resulted in a strong inhibition of arachidonic acid incorporation into the various cell lipids, indicating that arachidonic acid mobilization might be due to inhibition of reacylation processes. Reference: Biochem Pharmacol. 1989 Sep 1;38(17):2763-72. https://pubmed.ncbi.nlm.nih.gov/2505775/
In vivo activity:
CBA, H2k mice receiving a lethal dose of irradiation were injected with spleen cells from LF 1695-treated or untreated C57 Bl/6, H2b mice via different routes. Mice treated intraperitoneally with LF 1695 at 2.5 or 5 mg/kg/day showed an increase of GvHR intensity with splenic index of 1.71 and 1.80, respectively. When the animals were treated continuously through drinking water containing LF 1695 (4 mg/kg, 10 mg/kg or 100 mg/kg), these ratios were: 1.82, 1.10 and 1.37, respectively. Finally, LF 1695 enhanced GvHR significantly when used at low doses, while high doses induced a decrease of GvHR intensity. Reference: Int J Immunopharmacol. 1991;13(5):599-604. https://pubmed.ncbi.nlm.nih.gov/1838358/

Preparing Stock Solutions

The following data is based on the product molecular weight 328.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Hullin F, Ragab-Thomas JM, Sepulchre C, Pascal M, Chap H, Douste-Blazy L. Stimulation of 12-HETE production in human platelets by an immunomodulator, LF 1695. Evidence for activation of arachidonate liberation coupled to cyclo-oxygenase inhibition. Biochem Pharmacol. 1989 Sep 1;38(17):2763-72. doi: 10.1016/0006-2952(89)90429-2. PMID: 2505775. 2. Pascal M, Derrepas P. Increased interleukin-1 and modulation of interleukin-2 production by murine macrophages and lymphocytes treated with LF 1695. Int J Immunopharmacol. 1986;8(5):499-508. doi: 10.1016/0192-0561(86)90045-7. PMID: 3019905. 3. Othman O, Touraine JL, Sanhadji K, Pascal M. A new immunomodulator, LF 1695--II. Effects on allogenic and antigenic responses. Int J Immunopharmacol. 1991;13(5):599-604. doi: 10.1016/0192-0561(91)90082-i. PMID: 1838358. 4. Thorel T, Joseph M, Capron A, Vorng H, Pascal M. In vitro and in vivo immunomodulation by LF 1695 of human and rat macrophages and platelets in schistosomiasis. Int J Immunopharmacol. 1988;10(6):739-46. doi: 10.1016/0192-0561(88)90027-6. PMID: 3143681.
In vitro protocol:
1. Hullin F, Ragab-Thomas JM, Sepulchre C, Pascal M, Chap H, Douste-Blazy L. Stimulation of 12-HETE production in human platelets by an immunomodulator, LF 1695. Evidence for activation of arachidonate liberation coupled to cyclo-oxygenase inhibition. Biochem Pharmacol. 1989 Sep 1;38(17):2763-72. doi: 10.1016/0006-2952(89)90429-2. PMID: 2505775. 2. Pascal M, Derrepas P. Increased interleukin-1 and modulation of interleukin-2 production by murine macrophages and lymphocytes treated with LF 1695. Int J Immunopharmacol. 1986;8(5):499-508. doi: 10.1016/0192-0561(86)90045-7. PMID: 3019905.
In vivo protocol:
1. Othman O, Touraine JL, Sanhadji K, Pascal M. A new immunomodulator, LF 1695--II. Effects on allogenic and antigenic responses. Int J Immunopharmacol. 1991;13(5):599-604. doi: 10.1016/0192-0561(91)90082-i. PMID: 1838358. 2. Thorel T, Joseph M, Capron A, Vorng H, Pascal M. In vitro and in vivo immunomodulation by LF 1695 of human and rat macrophages and platelets in schistosomiasis. Int J Immunopharmacol. 1988;10(6):739-46. doi: 10.1016/0192-0561(88)90027-6. PMID: 3143681.
1: Touraine JL. Effect of the immunomodulator LF 1695 on T-lymphocytes and macrophages. Activity in HIV infection. Med Oncol Tumor Pharmacother. 1989;6(1):59-61. Review. PubMed PMID: 2657251. 2: Thorel T, Joseph M, Capron A, Vorng H, Pascal M. In vitro and in vivo immunomodulation by LF 1695 of human and rat macrophages and platelets in schistosomiasis. Int J Immunopharmacol. 1988;10(6):739-46. PubMed PMID: 3143681. 3: Hullin F, Ragab-Thomas JM, Sepulchre C, Pascal M, Chap H, Douste-Blazy L. Stimulation of 12-HETE production in human platelets by an immunomodulator, LF 1695. Evidence for activation of arachidonate liberation coupled to cyclo-oxygenase inhibition. Biochem Pharmacol. 1989 Sep 1;38(17):2763-72. PubMed PMID: 2505775. 4: Othman O, Touraine JL, Sanhadji K, Pascal M. A new immunomodulator, LF 1695--II. Effects on allogenic and antigenic responses. Int J Immunopharmacol. 1991;13(5):599-604. PubMed PMID: 1838358. 5: Pascal M, Derrepas P. Increased interleukin-1 and modulation of interleukin-2 production by murine macrophages and lymphocytes treated with LF 1695. Int J Immunopharmacol. 1986;8(5):499-508. PubMed PMID: 3019905. 6: Othmane O, Touraine JL, Sanhadji K, Pascal M. A new immunomodulator, LF 1695--I. In vitro effects on the T lymphocyte lineage in man. Int J Immunopharmacol. 1985;7(4):543-8. PubMed PMID: 2931384. 7: Derrepas P, Annat J, Dutartre P, Pascal M. Implications of prostaglandin E2 synthesis and phospholipase C activation in potentiation of T-cell proliferation by LF 1695. Int J Immunopharmacol. 1991;13(5):555-63. PubMed PMID: 1783469.